drugset / Trial / NCT05681377
Impact of Flumazenil on the Emergence Delirium
RandomizedParallel-groupTriple-blindPrevention
Summary
Flumazenil rapidly antagonizes benzodiazepines (BZDs); it may induce agitation, seizure, or delirium, especially when applied to patients who have taken BZDs for a long time. On the contrary, it may help patients regain consciousness in a stable and calm state by appropriately reversing the central nervous system depressant effects of BZDs. In this study, we aim to investigate the impact of flumazenil on the emergence delirium in patients anesthetized with remimazolam, the short-acting BZD drug.
Timeline
- Start
- 2023-03-05
- Primary completion
- 2023-08-11
- Completion
- 2023-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flumazenil | Small molecule | 0.2 mg | Intravenous |
Indications
No indication recorded.